The most important step in calcium homeostasis is the regulation of parathyroid hormone (PTH) secretion. The discovery and characterization of the calcium sensing receptor (CaR) of the parathyroid cell has led to a better understanding not only of the physiology of the parathyroid glands, but also of the development of hyperparathyroidism. Drugs acting on CaR can now be designed to treat hyperparathyroidism and osteoporosis.
INTRODUCTION
Guidelines for the treatment of asymptomatic primary hyperparathyroidism (PHPT) were agreed upon at a Consensus Development Conference held at the NIH in 1990 (1). Since then rapid development in many fields has given new insights into the pathogenesis, pathophysiology and clinical features of this disorder. Better procedures for preoperative localization of pathological parathyroid glands have led to the establishment of new operative strategies. The guidelines for treatment have been revised at a Workshop on Asymptomatic PHPT held at the NIH in 2002 (2). Progress within these areas during the last 15 years is presented in this review.
PATHOPHYSIOLOGY REGULATION OF PTH SECRETION VIA THE CALCIUM RECEPTOR, CaR
The level of extracellular calcium is maintained within strict limits by several homeostatic mechanisms. The most rapid response to changes in the concentration of calcium in the extracellular space takes place through the regulation of PTH secretion. There is a classical feed back loop between extracellular cal-cium and PTH secretion. It has long been known that extracellular calcium affects intracellular calcium in the parathyroid cells and that increased levels of intracellular calcium inhibit PTH secretion.
The link between extracellular and intracellular calcium was thought to reside in the channels that transport calcium over the cell membrane. However, in 1993 Brown and co-workers presented evidence that the calcium sensing mechanism was, in fact, a cell membrane-bound receptor (3). This receptor (CaR or CaSR) belongs to the G-protein-coupled, seven-transmembrane receptor superfamily, which includes receptors such as rhodopsin and the metabotropic glutamate receptor. Today, there is an abundance of literature on the properties of this receptor and its role, not only for the parathyroid cell, but also for the kidney and the CaR has a large amino-terminal extracellular domain consisting of about 600 amino acids. This part of the CaR molecule can sense free calcium ions as well as other divalent cations, like magnesium, and some amino acids (Fig. 1 ). The intracellular loops and the carboxy terminal part contain sites that can be phosphorylated by protein kinase C (PKC), which diminishes the signalling action of the receptor. CaR is present in the cell membrane in a dimeric configuration.
Signal transduction leading to inhibition of PTH secretion involves inhibitory and stimulatory G-proteins. CaR acts on an inhibitory G-protein and this causes inhibition of adenylate cyclase which reduces the amount of cyclic AMP needed for exocytosis of the PTH containing vesicles. The stimulatory pathway activates phospholipase C (PLC), which cleaves phosphatidyl inositolbisphosphate into inositoltrisphophate (InsP 3 ) and diacylglycerol (DAG). InsP 3 Fig. 1 . Schematic drawing of the parathyroid cell. Calcium receptor (CaR) in the cell membrane senses the extracellular calcium concentration. CaR can also be stimulated by other cations, L-amino acids and calcimimetics. The signal transduction chain involves stimulatory (Gqa) and inhibitory (Gia) G-proteins. Activation of phospholipase C (PLC) increases inositoltrisphosphate (InsP 3 ) which acts on InsP 3 -receptor (InsP 3 R) operated calcium channels to release calcium stored in the endoplasmic reticulum. The increased intracellular level of calcium, in turn, opens K + channels in the cell membrane. The outflow of K + causes hyperpolarization of the cell and inhibition of exocytosis of vesicles containing parathyroid hormone (PTH). Inhibition of adenylate cyclase (AC) decreases cyclic AMP (cAMP) needed for exocytosis. The increased level of diacylglycerol (DAG) stimulates protein kinase C (PKC) which can phosphorylate CaR to modulate (diminish) its action. Additional effects on cellular function are caused by PKC via mitogen-activated protein kinases (MAPK) and extracellular signal-regulated kinases (ERK). BK =BigK +channel. acts on a receptor-operated calcium channel in the endoplasmatic reticulum, which is the main intracellular store of calcium. This action of InsP 3 causes rapid release of calcium into the cytoplasm. The increased intracellular level of calcium, in turn, inhibits PTH secretion. The molecular mechanism for this inhibition has been unknown. An increase in intracellular calcium leads to an increased hormone secretion in most endocrine cells. We have recently used a patch clamp technique on isolated human parathyroid cells to show that, when intracellular calcium increases, voltage dependent potassium channels are opened and the cell becomes hyperpolarized (6). Hyperpolarization of the cell membrane may be the mechanism by which high intracellular calcium inhibits PTH secretion.
The results of the research on CaR have provided explanations to several clinical disorders and opened avenues for new therapeutic options (7). First, it has been shown that mutations in the CaR gene cause benign familial hypocalciuric hypercalcemia (FHH) (8, see also review ref 9). One copy of the gene has an inactivating mutation which decreases the sensitivity of the receptor to calcium and this, in turn, raises the secretion of PTH. The clinical picture is usually benign. Since one allele of the gene is normal, half the synthesized receptor protein is normal which reduces the detrimental effect of the mutated protein. If, however, both alleles are mutated, i.e., the individual is homozygous for the inactivating mutation, a severe condition known as neonatal severe hyperparathyroidism (NSHPT) develops. This life threatening condition is characterized by extremely high serum calcium levels and parathyroid hyperplasia. It can only be cured by total parathyroidectomy.
An activating mutation in CaR has also been described which leads to synthesis of a receptor protein that continuously signals via PLC/InsP 3 to decrease PTH secretion. The result is hypocalcemia. This condition was previously known as idiopathic hypocalcemia, but now as the genetic defect has been characterized it should be called autosomal dominant hypocalcemia.
Like other cell surface proteins, CaR can activate the immunological system. Activating and blocking antibodies have been described. The activating antibodies cause hypocalcemia. The blocking antibodies cause hypercalcemia in a condition characterized by lymphocytic infiltrates in the parathyroid glands (10) .
Pharmacologic agents acting on CaR have been synthesized. Agents stimulating CaR (calcimimetics) are effective in the treatment of secondary HPT and also, to some extent, of parathyroid cancer. Agents blocking CaR (calcilytics) stimulate the secretion of PTH and might be of value in the treatment of osteoporosis (11) .
The characteristic finding in primary hyperparathyroidism (PHPT) is that the level of PTH is inappropriately high in relation to serum calcium. It has been shown in vivo as well as in vitro that the "set-point" of PTH secretion is shifted to the right. Set-point is defined as the concentration of extracellular calcium needed to decrease PTH secretion to 50 % of maximum. It was initially expected that inactivating mu-tations of the CaR gene, similar to those in FHH, should be detected in parathyroid adenomas. However, no such mutations have been identified. It seems that one reason for the right-shifted set-point is decreased expression of CaR in the parathyroid adenomas (12) (13) . A similar phenomenon is seen in secondary HPT where the decreased expression may be secondary to proliferation. However, the relative roles of abnormal parathyroid cell proliferation and aberrant control of PTH secretion in the development of PHPT are not known.
CELL GROWTH
The parathyroid cell undergoes mitoses remarkably seldom. Under normal circumstances one cell division takes place each 30 years in adults, and thus parathyroid gland tumors should grow slowly. It is common clinical experience that many patients with hypercalcemia may be followed for years without significant progression. Only few patients show rapid increase in serum calcium requiring prompt medical and surgical intervention. This dual clinical picture has led to speculations about a different etiology in these two groups of patients (14) . In the first case, a mutation in a regulatory gene causes a shift in the set-point for PTH secretion. The new clone of parathyroid cells continues to divide and secrete PTH at high rate until serum calcium approaches the new set-point, when cell growth and secretion are attenuated. In the second case, rapid cell growth is caused by a mutation in a gene controlling the cell cycle. Progression causes life-threatening hypercalcemia. Parathyroid cancer is a good illustration of this type of tumor growth.
Usually PHPT is caused by a (single) adenoma, i.e., a monoclonal, benign tumor that develops due to genetic changes. The first described genetic event causing parathyroid adenoma was an inversion in chromosome 11 that puts the proto-oncogene PRAD1, which codes for the transcription factor cyclin D1, under the direct influence of the promoter region of the PTH gene (15) . An increased demand for the synthesis of PTH "speeds up" the cell cycle and leads to the development of a tumor. Although overexpression of cyclin D1 protein has been described in a significant proportion of parathyroid adenomas, this interesting chromosomal mechanism has been verified in less than a handful of tumors.
A clone of transgenic mice has offered new possibilities to study many aspects of HPT (16) . Mice transgenic for mimicking the human PTH-cyclin D1 gene rearrangement not only develop abnormal parathyroid cell proliferation, but also exhibit a shift in the relationship between serum calcium and PTH. Thus, it seems that a change in set-point may not be a primary, but rather a secondary event in HPT.
Another approach in the search for a genetic cause of sporadic parathyroid adenoma has been to study hereditary syndromes. The MEN1 gene related to the multiple endocrine neoplasia type 1 syndrome is associated with the development of approximately 30 % of all sporadic parathyroid adenomas. The molecular mechanism seems to be an interaction be-tween the menin protein and transcription factors leading to tumors. Another hereditary syndrome characterized by HPT is the HPT-jaw tumor syndrome (HPT-JT). This syndrome is caused by mutations in the HRPT2 gene coding for the protein parafibromin (17) . Parafibromin is probably also a transcription factor. Somatic mutations in the HRPT2 gene are often present in parathyroid cancer (18) . MEN1 and HRPT2 are both tumor suppressor genes.
Although some genetic mechanisms have been proven to cause parathyroid adenomas, the reason for tumorigenesis is still unknown in most cases.
CLINICAL PRESENTATION CLASSICAL VS NON-CLASSICAL SYMPTOMS
Much has been written about the change in clinical picture of PHPT since the introduction of the autoanalyzer. Gone are the days of the patients with advanced disease and severe bone and kidney disease. Many cases are now regarded as virtually asymptomatic. However, controversy exists between the views of clinical endocrinologists and endocrine surgeons. The criteria for operative treatment given by a recent workshop on asymptomatic PHPT (2) are presented in Table 1 and the recommendations for follow up of patients who do not undergo surgery are presented in Table 2 .
The non-traditional symptoms of PHPT, like neuropsychological dysfunction (weakness, easy fatigability, depression and intellectual weariness), have been put forward by surgeons as important indications for surgery, while medical endocrinologists are more hesitant to accept a proven causality. In spite of several studies indicating a positive effect of surgery on this kind of symptoms (19) (20) (21) (22) , the recent workshop stated that "they should not be regarded as sole criteria for surgery. Depending upon the clinical circumstances, however, the clinician might want to weigh them in the overall consideration of the patients' presenting clinical profile" (2).
Two recent studies have demonstrated that the non-specific somatic symptoms associated with PHPT occur with equal frequency in a group of patients meeting the NIH criteria compared with a group not meeting those citeria (23, 24) . A similar frequency of improvement took place after parathyroidectomy in both groups. The future will show whether surgeons are too optimistic about the therapeutic role of surgery in PHPT or whether the medical society has not seen the needs of their patients clearly enough. There is an apparent need for randomized, non-biased studies. Such a study is underway in Scandinavia, the Scandinavian Investigation of Primary Hyperparathyroidism (SIPH) in which "asymptomatic" patients are randomized to surgery or nonoperative follow up. Since many surgeons are reluctant to include patients with non-classical symptoms, it is questionable if this question will be answered.
A similar difference of views may be perceived between the European and the North American attitude toward the effect on PHPT on cardiovascular risk factors. While several Nordic studies have indicated that PHPT carries a significant risk of cardiovascular mortality (24) (25) (26) , no such risk has been demonstrated in an American population-based study, excluding, however, patients with the highest serum calcium levels (27) . Further studies are needed to resolve this issue.
Support for the view that PHPT may be a pathogenetic factor in cardiovascular disease is accumulating in several areas. Thus, deteriorated metabolic control as well as pathological endothelial function and disturbance of cardiac autonomic nerve function have been demonstrated in PHPT (28) (29) (30) .
The endpoint of the SIPH study is mortality, and better information on that aspect will undoubtedly be obtained within the next decade when results can be put together by the next generation of researchers.
SURGICAL STRATEGIES PREOPERATIVE LOCALIZATION, MINIMALLY INVASIVE OPERATION
Minimally invasive parathyroidectomy (MIP) has become increasingly popular among endocrine surgeons despite an initial hesitance to abandon the traditional bilateral neck exploration. A recent survey shows that 44 % of patients with PHPT are operated on with this approach; usually, a focused small incision technique is used (31) .
It seems that the main rationale for this change of practice has been economic (32) (33) . A limited procedure performed under general anesthesia with ultra shortacting intravenous drugs or local anesthesia permits day case surgery, which reduces the need for hospital beds. The published cure rate after short term follow up after MIP is similar to that of bilateral neck exploration (33-35; for comprehensive review see ref 36) .
A prerequisite for the new approach is reliable preoperative localization. A recent systematic meta- Recommendations for follow-up of patients who do not undergo surgery (Bilezikian et al 2002) .
Serum calcium biannually Serum creatinine biannually
Bone mineral density (spine, hip, forearm) annually analysis of the literature on sestamibi scintigraphy shows that the published sensitivity varies between 39 % and >90%, with a median of 71.5 % (37) . However, the same authors conclude from their own experience that the sensitivity in clinical practice may be considerably lower, 45 %. The sensitivity of sonography is similar to or slightly lower than that of scintigraphy (38) . It is obviously no surprise that the combination of both methods results in a fairly low frequency of concordant results. Concordant results on imaging have, nevertheless, a positive predictive value of nearly 100 %, and this provides a solid base for focused surgery (38) . It has been suggested that a reasonable strategy would be to use one or the other imaging methods initially and then to follow with the alternate method if the first test is negative.
It has been pointed out that there is a selection bias in most reported series of MIP and that the operation has been scan-selected rather than scan-directed (39) . In the only published randomized study the cases were scan-selected (40) . Thus, the real place for MIP in an unselected population of patients with PHPT has not been determined.
The cost-effectiveness of MIP is difficult to judge from the literature, since the cost of negative localization seems to be underestimated or not taken into account at all in most series.
The only way to get a reliable answer to the question whether the new technique is better than the old is to perform a randomized study. It can be assumed that a randomized study would uncover some of the difficulties with the MIP that escape notice when retrospective analyses are made.
A focused approach leads to removal of a single pathological parathyroid gland. In contrast, bilateral neck exploration results in removal of multiple pathological glands in a significant proportion of patients (41) (42) . Yet the short term results of these two approaches seem to be the same. Three reasons have been discussed. First, the two techniques are not comparable due to patient selection. Patients with a single adenoma have positive scans and are operated on with a focused approach. Second, some macroscopically enlarged glands which are microscopically pathological are not hyperfunctioning, but are unnecessarily removed during bilateral neck exploration. Third, the focused approach gives good short term results, but will result in a higher frequency of recurrences in the long run.
Most centers performing MIP today use preoperative localization in conjunction with intraoperative determination of PTH. This type of approach may decrease the risk of missing a second or third pathological gland. However, the method may fail when it is most needed, since the false positive rate in double adenomas is no less than 50 % (43, 44) . The reason for this failure might be different set-points in the two adenomas: the clone of parathyroid cells with the lower set-point would stop growing earlier than the clone with the higher set-point, resulting in a smaller adenoma that would contribute less to serum PTH as long as the bigger adenoma with higher setpoint is still present. Once the bigger adenoma is removed, PTH will fall until serum calcium decreases below the set-point of the second adenoma, when synthesis of PTH in the smaller adenoma speeds up and after a few days raises serum calcium, now to a lower level than before the removal of the first adenoma. Evidently not all problematic cases are cured when PTH analysis is included in the assessment, and this observation should be related to the high cost of PTH determinations.
The economic impact of preoperative localization depends on the type of operative technique (32) . The most important cost saving measure is early discharge of the patient from the hospital. Swedish surgeons (and patients) have been slow in accepting same day discharge as good practice. Increasing demands for cost-effectiveness will probably change this view in the future.
To summarize, many studies have shown that a MIP is feasible once preoperative localization studies have been done. The outcome is probably no different from that of bilateral neck exploration. However, a prerequisite for reaching economic benefit is that the procedure can be performed on a day case basis.
